ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update August 15, 2022
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis August 15, 2022
ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis July 13, 2022
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections June 14, 2022
ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022 June 6, 2022
ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone April 27, 2022
ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting April 18, 2022
ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update March 24, 2022
